Genmab to Submit Biologics License Application to U.S. Food
Company Announcement COPENHAGEN, Denmark; June 30, 2022 – Genmab A/S (Nasdaq: GMAB) today announced its intent to submit a biologics license application...
Source: globenewswire.com
Page 5 - Cell Surface News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Cell Surface. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Cell Surface Today - Breaking & Trending Today
Genmab Announces Late-Breaking Phase 2 Trial Results of Investigational Epcoritamab (DuoBody®-CD3xCD
Epcoritamab demonstrated clinically meaningful efficacy in challenging to treat, highly refractory LBCL patients, including patients previously treated with chimeric antigen receptor (CAR) T-cell therapyTotal patient population achieved overall response rate (ORR) of 63 percent and complete response (CR) of 39 perce...
Source: pharmiweb.com
Genmab Announces Late-Breaking Phase 2 Trial Results of Investigational Epcoritamab (DuoBody-CD3xCD20) in Relapsed/Refractory Large B-cell Lymphoma (LBCL) Patients Presented at European Hematology Association (EHA) Presidential Symposium
Epcoritamab demonstrated clinically meaningful efficacy in challenging to treat, highly refractory LBCL patients, including patients previously treated with chimeric antigen receptor (CAR) T-cell
Source: finanznachrichten.de
Genmab Announces Multiple Abstracts to be Presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
Press release content from Business Wire. The AP news staff was not involved in its creation.
Source: apnews.com
2022-05-26 | NDAQ:GMAB | Press Release
(2022-05-26 | NDAQ:GMAB) Genmab Announces Multiple Abstracts to be Presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
Source: stockhouse.com